ClinConnect ClinConnect Logo
Search / Trial NCT06277908

Postoperative Morbidity and Mortality After Gastric Cancer Surgery

Launched by P. HERZEN MOSCOW ONCOLOGY RESEARCH INSTITUTE · Feb 18, 2024

Trial Information

Current as of July 23, 2025

Not yet recruiting

Keywords

Gastric Cancer Surgery Morbidity Mortality

ClinConnect Summary

This clinical trial is focused on understanding the outcomes of surgery for gastric cancer, specifically looking at the complications and risks that patients may face after their surgery. Gastric cancer is a serious condition, and surgery is currently the best option for a cure. However, the results of surgery can vary widely depending on where the procedure is performed. The researchers want to study how many patients experience complications and deaths within 90 days after surgery across different hospitals in Russia. This information will help improve future treatment guidelines.

To participate in this trial, patients should be adults aged 18 or older who have been diagnosed with primary gastric cancer and are scheduled for elective surgery with the aim of curing their cancer. Unfortunately, patients with certain other types of cancer or those needing emergency surgery won't be eligible. If you join the trial, you can expect to be closely monitored after your surgery to track any complications and to provide valuable information that could help improve care for future patients.

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • All consecutive patients with primary gastric malignancy (including Siewert III) undergoing elective surgery with curative intent (either total or partial gastrectomy) via open, laparoscopic or robotic approach between 18th March 2024 and 18th September 2024.
  • Exclusion Criteria:
  • Patients with clinical evidence of metastatic disease, including positive peritoneal cytology on previous staging laparoscopy,
  • Patients with known synchronous cancer;
  • Patients with Gastrointestinal stromal tumors (GIST)
  • Presence of gastroesophageal junction (Siewert I and II) malignancy;
  • Patients submitted to Emergency surgery or surgery without curative intent;
  • Patients undergoing additional surgery (except cholecystectomy) along with surgery for gastric cancer.

About P. Herzen Moscow Oncology Research Institute

The P. Herzen Moscow Oncology Research Institute is a leading clinical research organization dedicated to advancing cancer treatment and care. With a rich history in oncology research, the institute focuses on innovative therapies and comprehensive clinical trials aimed at improving patient outcomes. By integrating cutting-edge scientific methods with clinical expertise, the institute fosters collaboration among researchers, healthcare professionals, and patients to drive breakthroughs in cancer treatment. Its commitment to excellence and patient-centered care positions it as a prominent sponsor in the field of oncology research.

Locations

Moscow, , Russian Federation

Moscow, , Russian Federation

Moscow, , Russian Federation

Rostov On Don, , Russian Federation

Moscow, , Russian Federation

Moscow, , Russian Federation

Moscow, , Russian Federation

Nizhny Novgorod, , Russian Federation

Saint Petersburg, , Russian Federation

Patients applied

0 patients applied

Trial Officials

Andrey Ryabov, MD, PhD

Study Director

P.Herzen Moscow Oncological Research Institute

Vladimir Khomyakov, MD, PhD

Principal Investigator

P.Herzen Moscow Oncological Research Institute

Nuriddin Abdulkhakimov, MD, PhD

Principal Investigator

P.Herzen Moscow Oncological Research Institute

Pavel Smirnov

Principal Investigator

P.Herzen Moscow Oncological Research Institute

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported